<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03133676</url>
  </required_header>
  <id_info>
    <org_study_id>CBR-KA34-3001</org_study_id>
    <nct_id>NCT03133676</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of KA34 in Subjects With Knee Osteoarthritis</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of KA34 Administered Via Intra-Articular Injection in Subjects With Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Calibr, a division of Scripps Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>California Institute for Regenerative Medicine (CIRM)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Calibr, a division of Scripps Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and tolerability of KA34 when administered via
      intra-articular injection to subjects with osteoarthritis of the knee.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled study to assess the safety,
      tolerability, pharmacokinetics, and pharmacodynamics of KA34 when administered via
      intra-articular injection to subjects with osteoarthritis of the knee. OA patients are
      randomized to receive either placebo or KA34 active drug in the range of 50-400 ug by
      intra-articular injection. The first portion of the study is with single ascending doses, the
      second portion of the study is with multiple ascending doses.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2, 2018</start_date>
  <completion_date type="Actual">April 28, 2020</completion_date>
  <primary_completion_date type="Actual">April 28, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Day 29 or Day 180</time_frame>
    <description>Incidence, relatedness, severity, and duration of treatment emergent adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Laboratory Tests</measure>
    <time_frame>Day 29 or Day 180</time_frame>
    <description>Change from baseline in clinical laboratory test results</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Vital Signs</measure>
    <time_frame>Day 29 or Day 180</time_frame>
    <description>Change from baseline in vital sign measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in ECG</measure>
    <time_frame>Day 29 or Day 180</time_frame>
    <description>Change from baseline in electrocardiogram results</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical Examination Findings</measure>
    <time_frame>Day 29 or Day 180</time_frame>
    <description>Clinically significant findings on physical examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameter - Cmax</measure>
    <time_frame>Day 8 or Day 29</time_frame>
    <description>Maximum observed plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameter - Tmax</measure>
    <time_frame>Day 8 or Day 29</time_frame>
    <description>Time to maximum observed plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameter - AUC</measure>
    <time_frame>Day 8 or Day 29</time_frame>
    <description>Area under the plasma concentration vs. time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameter - t 1/2</measure>
    <time_frame>Day 8 or Day 29</time_frame>
    <description>Terminal half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameter - CL/F</measure>
    <time_frame>Day 8 or Day 29</time_frame>
    <description>Apparent clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameter - Vz/F</measure>
    <time_frame>Day 8 or Day 29</time_frame>
    <description>Volume of distribution</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>KA34 Active Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KA34 active drug in the dose range of 50 - 400 ug per knee</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo is the formulation for KA34.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KA34</intervention_name>
    <description>50 µg - 400 µg intra-articular injection (single or multiple doses)</description>
    <arm_group_label>KA34 Active Drug</arm_group_label>
    <other_name>KA-34</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>50 µg - 400 µg intra-articular injection (single or multiple doses)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of localized osteoarthritis of the knee

          -  Males willing to use contraception and females who are no longer able to bear children

        Exclusion Criteria:

          -  Body Mass Index (BMI) &gt; 40

          -  Grade 3 or 4 osteoarthritis on the Kellgren and Lawrence classification system

          -  Injury to the knee or other joint within the last 12 months

          -  Receipt of any investigational product or experimental therapeutic procedure within
             the last 12 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Lotz, MD</last_name>
    <role>Study Director</role>
    <affiliation>Calibr, a division of Scripps Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Diablo Clinical Research</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of West Florida</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bioclinica Research</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altoona Center for Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>April 20, 2017</study_first_submitted>
  <study_first_submitted_qc>April 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2017</study_first_posted>
  <last_update_submitted>April 28, 2020</last_update_submitted>
  <last_update_submitted_qc>April 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoarthritis</keyword>
  <keyword>Arthritis</keyword>
  <keyword>Joint Disease</keyword>
  <keyword>Osteoarthritis, Knee</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

